Clinical review for general practice

ISSN (Print) 2713-2552
ISSN (Online) 2782-5671
  • Home
  • about
  • archives
  • contacts
left
FULLSCREEN > Archive > 2024 > Vol 5, №7 (2024) > Clinical observation of a complete clinical, radiological and pathomorphological response in a patient with locally advanced gastric adenocarcinoma after neoadjuvant therapy

Clinical observation of a complete clinical, radiological and pathomorphological response in a patient with locally advanced gastric adenocarcinoma after neoadjuvant therapy

Diana Yu. Mironova , Vitaliy Yu. Skoropad , Natalya K. Silanteva , Tatev A. Agababyan1 , Ekaterina S. Zhavoronkova , Sergey A. Ivanov , Andrey D. Kaprin

For citation:


  • Abstract
  • About the Author
  • References

Abstract

Stomach cancer is an aggressive disease and represents a global health problem. Currently, more than 50% of patients with a newly diagnosed stomach cancer have a locally advanced process that requires a combined approach – a combination of surgical treatment and neoadjuvant/perioperative therapy. In a number of patients, after neoadjuvant therapy, there is a marked or even complete regression of the tumor; the prognosis of the disease, as well as the need for adjuvant therapy in this category of patients is the subject of discussion. This paper demonstrates the clinical observation of a complete clinical, radiological and morphological response after neoadjuvant therapy (2 cycles of chemotherapy FLOT + chemoradiotherapy), as well as long-term relapse-free survival in a patient with locally advanced gastric cancer.
Keywords: locally advanced gastric cancer, neoadjuvant therapy, complete tumor response, survival.


About the Author

Diana Yu. Mironova 1 , Vitaliy Yu. Skoropad 1 , Natalya K. Silanteva 1 , Tatev A. Agababyan1 1 , Ekaterina S. Zhavoronkova 1 , Sergey A. Ivanov 2 , Andrey D. Kaprin 3

1 Tsyb Medical Radiological Research Centre – branch of the National Medical Research Radiological Centre, Obninsk, Russia

2 Tsyb Medical Radiological Research Centre – branch of the National Medical Research Radiological Centre, Obninsk, Russia; Patrice Lumumba People’s Friendship University of Russia (RUDN University), Moscow, Russia

3 National Medical Research Radiological Centre of the Ministry of Health of the Russian Federation, Moscow, Russia; Patrice Lumumba People’s Friendship University of Russia (RUDN University), Moscow, Russia; Hertsen Moscow Oncology Research Institute – bra

References

1. Шахзадова А.О., Старинский В.В., Лисичникова И.В. Состояние онкологической помощи населению России в 2022 году. Сибирский онкологический журнал. 2023;22(5):5-13. DOI: 10.21294/1814-4861-2023-22-5-5-13 Shakhzadova A.O., Starinsky V.V., Lisichnikova I.V. Cancer care to the population of Russia in 2022. Siberian journal of oncology. 2023;22(5):5-13. DOI: 10.21294/1814-4861-2023-22-5-5-13 (in Russian).
2. Al-Batran SE, Homann N, Pauligk C et al. Perioperative chemotherapy with fluorouracil plus leucovorin, oxaliplatin, and docetaxel versus fluorouracil or capecitabine plus cisplatin and epirubicin for locally advanced, resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4): a randomised, Phase 2/3 trial. Lancet. 2019;393:1948-57. DOI: 10.1016/S0140-6736(18)32557-1
3. Leong T, Smithers BM, Haustermans K et al. TOPGEAR: A Randomized, Phase III Trial of Perioperative ECF Chemotherapy with or Without Preoperative Chemoradiation for Resectable Gastric Cancer: Interim Results from an International, Intergroup Trial of the AGITG, TROG, EORTC and CCTG. Ann Surg Oncol. 2017;24(8):2252-8. DOI: 10.1245/s10434-017-5830-6
4. Скоропад В.Ю., Миронова Д.Ю., Колобаев И.В. и др. Анализ токсичности при проведении неоадъювантной индукционной химиотерапии и последующей химиолучевой терапии у больных местно-распространенным раком желудка. Онкология. Журнал им. П.А. Герцена. 2024;13(2):15-20. DOI: 10.17116/onkolog20241302115 Skoropad V.Yu., Mironova D.Yu., Kolobaev I.V. et al. Toxicity analysis during neoadjuvant induction chemotherapy and subsequent chemoradiotherapy in patients with locally advanced gastric cancer. P.A. Herzen Journal of Oncology. 2024;13(2):15-20. DOI: 10.17116/onkolog20241302115 (in Russian).
5. Petrelli F, Tomasello G, Barni S. Surrogate end-points for overall survival in 22 neoadjuvant trials of gastro-oesophageal cancers. Eur J Cancer. 2017;76:8-16. DOI: 10.1016/j.ejca.2017.01.032
6. Lin C, Ma J, Zhu C et al. Is Pathologic Complete Response a Good Predictor for the Long-Term, Clinical Outcome in Patients with Gastric Cancer After Neoadjuvant Chemotherapy? A Retrospective, Multi-institution Study in China. Ann Surg Oncol. 2023;30;5534-42. DOI: 10.1245/s10434-023-13728-5
7. Kaltenmeier C, Althans A, Mascara M et al. Pathologic Complete Response Following Neoadjuvant Therapy for Gastric Adenocarcinoma: 
A National Cancer Database Analysis on Incidence, Predictors, 
and Outcomes. Am Surg. 2021;87(7):1145-54. DOI: 10.1177/ 0003134820972083
8. Trumbull DA, Lemini R, Díaz Vico T et al. Prognostic Significance of Complete Pathologic Response Obtained with Chemotherapy Versus Chemoradiotherapy in Gastric Cancer. Ann Surg Oncol. 2021;28:766-73. DOI: 10.1245/s10434-020-08921-9
9. Zhu Y, Chen J, Sun X et al. Survival and complications after neoadjuvant chemoradiotherapy versus neoadjuvant chemotherapy for locally advanced gastric cancer: a systematic review and meta-analysis. Front Oncol. 2023;13:1177557. DOI: 10.3389/fonc.2023.1177557
10. Fernandez LM, São Julião GP, Figueiredo NL et al; International Watch & Wait Database Consortium. Conditional recurrence-free survival of clinical complete responders managed by watch and wait after neoadjuvant chemoradiotherapy for rectal cancer in the International watch & wait database: a retrospective, international, multicentre registry study. Lancet Oncol. 2021;22:43-50. DOI: 10.1016/S1470-2045(20)30557-X


For citation:Mironova D.Yu., Skoropad V.Yu., Silanteva N.K., Agababian T.A., Zhavoronkova E.S., Ivanov S.A., Kaprin A.D. clinical observation of a complete clinical, radiological and pathomorphological response in a patient with locally advanced gastric adenocarcinoma after neoadjuvant therapy. Clinical review for general practice. 2024; 5 (7): 6-11. (In russ.). doI: 10.47407/kr2024.5.7.00442


All accepted articles publish licensed under a Attribution-NonCommercial-ShareAlike 4.0 International (CC BY-NC-SA 4.0) which allows users to read, copy, distribute and make derivative works for non-commercial purposes from the material, as long as the author of the original work is cited properly.

  • About
  • Editorial board
  • Ethics
  • For authors
  • Author fees
  • Peer review
  • Contacts

oa
crossref
анри


  Indexing

doaj
elibrary

Address of the Editorial Office:

127055, Moscow, s/m 37

Correspondence address:

115054, Moscow, Zhukov passage, 19, fl. 2, room XI


Managing Editor:

+7 (495) 926-29-83

id@con-med.ru